世界のmRNA癌ワクチン及び治療薬市場規模・現状・予測2018-2030

【英語タイトル】Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2018-2030

QYResearchが出版した調査資料(QYR810ZA08)・商品コード:QYR810ZA08
・発行会社(調査会社):QYResearch
・発行日:2018年10月
・ページ数:約140
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥440,700見積依頼/購入/質問フォーム
Enterprise(全社内共有可)USD7,800 ⇒換算¥881,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

This report studies the mRNA Vaccines & Therapeutics market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the mRNA Vaccines & Therapeutics market by product type and applications.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

The major players in global mRNA Vaccines & Therapeutics market include

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of mRNA Vaccines & Therapeutics in these regions, from 2020 to 2030 (forecast), covering

North America

Europe

Asia Pacific

South America

Middle East and Africa

On the basis on the end users/applications, this report covers

Infectious Disease

Cancer

Other

【レポートの目次】

1 Report Overview 1

1.1 Study Scope 1

1.2 Key Market Segments 1

1.3 Players Covered 2

1.4 Market by Application 2

1.4.1 Global mRNA Cancer Vaccines and Therapeutics Expenses Comparison by Applications (2013-2025) 2

1.4.2 Infectious Disease 4

1.4.3 Cancer 4

1.5 Study Objectives 5

1.6 Years Considered 5

2 Global Growth Trends 6

2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size 6

2.2 mRNA Cancer Vaccines and Therapeutics Growth Trends by Regions 7

2.2.1 mRNA Cancer Vaccines and Therapeutics Expense by Regions (2013-2025) 7

2.2.2 mRNA Cancer Vaccines and Therapeutics Market Share by Regions (2013-2018) 7

2.3 Industry Trends 9

2.3.1 Market Top Trends 9

2.3.2 Substitutes Threat 11

2.3.3 DNA/mRNA Advantages over Traditional Vaccines 12

3 Market Share by Key Players 13

3.1 mRNA Cancer Vaccines and Therapeutics Market Size by Manufacturers 13

3.1.1 Global mRNA Cancer Vaccines and Therapeutics Expenses by Manufacturers (2017-2018) 13

3.1.2 Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Manufacturers (2017-2018) 13

3.1.3 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR3) 15

3.2 mRNA Cancer Vaccines and Therapeutics Key Players Head office and Area Served 16

3.3 Pipeline Analysis of mRNA Cancer Vaccines and Therapeutics 16

3.4 Date of Enter into mRNA Cancer Vaccines and Therapeutics Market 17

3.5 Mergers & Acquisitions, Expansion Plans 17

4 Breakdown Data by Application 20

5 North America 23

5.1 North America mRNA Cancer Vaccines and Therapeutics Expense (2013-2018) 23

5.2 North America mRNA Cancer Vaccines and Therapeutics Expense and Market Share by Players 23

5.3 North America mRNA Cancer Vaccines and Therapeutics Expense and Market Share by Applications 25

6 Europe 27

6.1 Europe mRNA Cancer Vaccines and Therapeutics Expenses (2013-2018) 27

6.2 Europe mRNA Cancer Vaccines and Therapeutics Expenses and Market Share by Players 27

6.3 Europe mRNA Cancer Vaccines and Therapeutics Expenses and Market Share by Applications 29

7 Major Cancer Analysis 31

7.1 Colorectal Cancer 31

7.1.1 Colorectal Cancer Introduction 31

7.1.2 Introduction of the Number of Patients with Colorectal Cancer 31

7.2 Lung Cancer 32

7.2.1 Lung Cancer Introduction 32

7.2.2 Introduction of the Number of Patients with Lung Cancer 33

7.3 Pancreatic Cancer 35

7.3.1 Pancreatic Cancer Introduction 35

7.3.2 Introduction of the Number of Patients with Pancreatic Cancer 35

7.4 Breast Cancer 36

7.4.1 Breast Cancer Introduction 36

7.4.2 Introduction of the Number of Patients with Breast Cancer 37

7.5 Prostate Cancer 38

7.5.1 Prostate Cancer Introduction 38

7.5.2 Introduction of the Number of Patients with Prostate Cancer 38

7.6 Other Cancer 40

8 Company Profiles 42

8.1 Companies with mRNA Programs 42

8.1.1 Alexion Pharmaceuticals 42

8.1.2 Vertex Pharmaceuticals 43

8.1.3 Ultragenyx Pharmaceutical 44

8.2 Companies focus on mRNA Delivery 45

8.2.1 Acuitas Therapeutics 45

8.2.2 Silence Therapeutics 47

8.2.3 Arcturus Therapeutics 48

9 Pipeline Analysis of mRNA Cancer Vaccines and Therapeutics Key Manufacturers 51

9.1 Pipeline Analysis of mRNA Cancer Vaccines and Therapeutics 51

9.2 Main Pipeline Product Analysis 52

9.2.1 IVAC-Mutanome 52

9.2.2 FixVax 52

9.2.3 CV8102 52

9.2.4 CV7201 53

9.2.5 AGS-004 53

9.2.6 MRT5005 & MRT5201 54

9.2.7 SB-FIX & SB-318 & SB-913 54

9.2.8 mRNA-1647 55

9.2.9 mRNA-4157 56

9.2.10 mRNA-1653 56

10 Major Pharmaceutical Companies with mRNA Programs 57

10.1 Boehringer Ingelheim 57

10.2 Novartis 58

10.3 Merck 59

10.4 AstraZeneca 60

10.5 Roche 61

10.6 Sanofi 62

10.7 Takeda 63

10.8 Johnson & Johnson 64

10.9 Bayer 65

10.10 ZIOPHARM Oncology 66

10.11 MaxCyte 67

10.12 Casebia Therapeutics 68

10.13 Intellia Therapeutics 71

11 mRNA Cancer Vaccines and Therapeutics Manufacturing Cost Analysis 73

11.1 mRNA Cancer Vaccines and Therapeutics Key Raw Materials Analysis 73

11.1.1 Clinical Phase Costs 74

11.1.2 Capitalized Costs 75

11.2 Proportion of Manufacturing Cost Structure 76

11.2.1 Raw Materials 76

11.2.2 Labor Cost 76

11.2.3 Other Costs Analysis 82

11.2.4 Manufacturing Expenses 86

11.3 Comparison of Production Processes for Traditional, mRNA and DNA vaccines 87

12 Analysis of mRNA Cancer Vaccines and Therapeutics Industry Key Manufacturers 90

12.1 Moderna Therapeutics 90

12.1.1 Company Profile 90

12.1.2 Product Information 91

12.1.3 Expenses, R&D Share 93

12.2 CureVac 93

12.2.1 Company Profile 93

12.2.2 Product Information 94

12.2.3 Expenses, R&D Share 95

12.3 RaNa Therapeutics (Translate Bio) 96

12.3.1 Company Profile 96

12.3.2 Product Information 97

12.3.3 Expenses, R&D Share 97

12.4 BioNTech 98

12.4.1 Company Profile 98

12.4.2 Product Information 99

12.4.3 Expenses, R&D Share 100

12.5 Sangamo Therapeutics 100

12.5.1 Company Profile 100

12.5.2 Product Information 101

12.5.3 Expenses, R&D Share 101

12.6 Argos Therapeutics 102

12.6.1 Company Profile 102

12.6.2 Product Information 103

12.6.3 Expenses, R&D Share 104

12.7 In-Cell-Art 104

12.7.1 Company Profile 104

12.7.2 Product Information 105

12.7.3 Expenses, R&D Share 106

12.8 eTheRNA 107

12.8.1 Company Profile 107

12.8.2 Product Information 108

12.8.3 Expenses, R&D Share 108

12.9 Ethris 109

12.9.1 Company Profile 109

12.9.2 Product Information 110

12.9.3 Expenses, R&D Share 110

12.10 Tiba Biotechnology 110

12.10.1 Company Profile 110

12.10.2 Product Information 112

12.10.3 Expenses, R&D Share 112

13 Market Forecast 2020-2030 113

13.1 Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast (2020-2030) 113

13.2 Global mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast by Regions (2020-2030) 114

13.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 114

13.2.2 North America mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 116

13.2.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 117

13.2.4 Asia Pacific mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 118

13.2.5 South America mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 119

13.2.6 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate Forecast (2020-2030) 120

13.3 Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Application (2020-2030) 120

14 Analyst’s Viewpoints/Conclusions 122

15 Appendix 123

15.1 Research Methodology 123

15.1.1 Methodology/Research Approach 123

15.1.2 Data Source 127

15.3 Author Details 129

List of Table and Figure

Figure Product Picture of mRNA Cancer Vaccines and Therapeutics 1

Table mRNA Cancer Vaccines and Therapeutics Key Market Segments 1

Table Key Players mRNA Cancer Vaccines and Therapeutics Covered 2

Table Scope of Clinical mRNA Applications 2

Figure Global Expenses Market Share of mRNA Cancer Vaccines and Therapeutics by Applications in 2017 3

Figure Infectious Disease Examples 4

Figure Cancer Examples 4

Figure mRNA Cancer Vaccines and Therapeutics Report Years Considered 5

Figure Global Market mRNA Cancer Vaccines and Therapeutics Revenue (M USD) Comparison by Regions 2020-2030 6

Table Global mRNA Cancer Vaccines and Therapeutics Expense (M USD) by Regions 2013-2025 (M USD) 7

Table Global mRNA Cancer Vaccines and Therapeutics Expenses (M USD) and Market Share by Regions (2013-2018) 7

Table Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Regions (2013-2018) 7

Figure Expenses Market Share of mRNA Cancer Vaccines and Therapeutics by Regions (2013-2018) 8

Figure Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Regions in 2017 9

Figure mRNA Cancer Vaccines and Therapeutics Discovery and Development Analysis 9

Figure Picture of RNAi for Therapeutic 11

Table Global mRNA Cancer Vaccines and Therapeutics Expenses by Manufacturers (2017-2018) (M USD) 13

Table Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Manufacturers (2017-2018) 13

Figure Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Manufacturers in 2017 14

Figure Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Manufacturers in 2018 15

Table Global mRNA Cancer Vaccines and Therapeutics Manufacturers Market Concentration Ratio (CR3) in 2017 15

Table Key Players Head office and Area Served 16

Table Pipeline Analysis mRNA Cancer Vaccines and Therapeutics 16

Table Date of Enter into mRNA Cancer Vaccines and Therapeutics Market 17

Table Global mRNA Cancer Vaccines and Therapeutics Expenses (M USD) by Application (2013-2018) 20

Table Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Application (2013-2018) 20

Figure Expenses Market Share of mRNA Cancer Vaccines and Therapeutics by Application (2013-2018) 21

Figure Global mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Application in 2017 22

Figure North America mRNA Cancer Vaccines and Therapeutics Expenses (M USD) and Growth Rate (2013-2018) 23

Table North America mRNA Cancer Vaccines and Therapeutics Expenses (M USD) by Players (2017-2018) 23

Table North America mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Players (2017-2018) 24

Figure North America mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Players in 2017 24

Table North America mRNA Cancer Vaccines and Therapeutics Expenses (M USD) by Applications (2013-2018) 25

Table North America mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Applications (2013-2018) 25

Figure North America mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Applications in 2017 26

Figure Europe mRNA Cancer Vaccines and Therapeutics Expenses (M USD) and Growth Rate (2013-2018) 27

Table Europe mRNA Cancer Vaccines and Therapeutics Expenses (M USD) by Players (2017-2018) 27

Table Europe mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Players (2017-2018) 28

Figure Europe mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Players in 2017 28

Table Europe mRNA Cancer Vaccines and Therapeutics Expenses (M USD) by Applications (2013-2018) 29

Table Europe mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Applications (2013-2018) 29

Figure Europe mRNA Cancer Vaccines and Therapeutics Expenses Market Share by Applications in 2017 30

Top 20 Countries Highest Incidence of Colorectal Cancer in 2016 32

Top 20 Countries Highest Incidence of Lung Cancer in 2016 33

Figure Percent of New Cases by Age Group: Lung Cancer 34

Figure Percent of Deaths by Age Group: Lung Cancer 34

Top 20 Countries Highest Incidence of Pancreatic Cancer in 2016 36

Top 20 Countries Highest Incidence of Breast Cancer in 2016 37

Figure Percent of New Cases by Age Group: Prostate Cancer 39

Figure Percent of Deaths by Age Group: Prostate Cancer 39

Figure Estimated Prostate Cancer Incidence Worldwide in 2016 40

Information about World Cancer Statistics for the Most Common Cancers (excluding non-melanoma Skin Cancer) in 2016 40

Table Alexion Pharmaceuticals Company Profile 42

Table Vertex Pharmaceuticals Company Profile 43

Table Ultragenyx Pharmaceutical Company Profile 44

Table Acuitas Therapeutics Company Profile 45

Figure mRNA Cancer Vaccines and Therapeutics Product Information of Acuitas Therapeutics 46

Table Silence Therapeutics Company Profile 47

Table Table Product Information 47

Table Arcturus Therapeutics Company Profile 48

Table Product Information 49

Table Pipeline Analysis mRNA Cancer Vaccines and Therapeutics 51

Figure IVAC-Mutanome Pipeline 52

Figure FixVax Pipeline 52

Figure CV8102 Pipeline 52

Figure CV7201 Pipeline 53

Figure CV7201 Pipeline 53

Figure MRT5005 & MRT5201 Pipeline 54

Figure SB-FIX Pipeline 54

Figure SB-318 & SB-913 Pipeline 54

Figure mRNA-1647 Pipeline 55

Figure mRNA-4157 Pipeline 56

Figure mRNA-1653 Pipeline 56

Table Boehringer Ingelheim Company Profile 57

Table Novartis Company Profile 58

Table Merck Company Profile 59

Table AstraZeneca Company Profile 60

Table Roche Company Profile 61

Table Sanofi Company Profile 62

Table Takeda Company Profile 63

Table Johnson & Johnson Company Profile 64

Table Bayer Company Profile 65

Table ZIOPHARM Oncology Company Profile 66

Figure mRNA Cancer Vaccines and Therapeutics Product Information of ZIOPHARM Oncology 67

Table MaxCyte Company Profile 67

Table Casebia Therapeutics Company Profile 68

Figure mRNA Cancer Vaccines and Therapeutics Product Information of Casebia Therapeutics 70

Table Intellia Therapeutics Company Profile 71

Table Product Information 72

Figure Typical Phases from Research to the Market for a Cancer Vaccine Candidate 74

Table Out-of-pocket Preclinical and Clinical Period Cost Per Investigational Biopharmaceutical Compound 75

Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 76

Figure USA Labor Cost Analysis 2015-2018 76

Figure Cost of Employing a Factory Worker 77

Figure Europe Labor Cost Analysis 2015-2018 78

Figure Germany Labor Cost Analysis 2015-2018 78

Figure UK Labor Cost Analysis 2015-2018 79

Figure France Labor Cost Analysis 2015-2018 79

Figure Italy Labor Cost Analysis 2015-2018 79

Figure Monthly Minimum Wages in Asia 2016 80

Figure China Labor Costs 2015-2018 80

Figure Japan Average Monthly Wages 2015-2018 81

Figure Global Electricity Prices by Select Countries in 2017 (in U.S. Dollars per Kilowatt Hour) 82

Table Average Price of Electricity to Ultimate Customers 2007-2018 83

Figure Electricity Prices for Household Consumers in 2017 84

Table China Cost of Electricity 2017 (PER KWH) 85

Figure Comparison of Production Processes for Traditional, mRNA and DNA Vaccines 87

Figure Differences between Traditional, mRNA and DNA Vaccines 88

Figure History of Vaccine Development 88

Figure Differences between Traditional, MRNA and DNA Vaccines (Delivery) 89

Table Moderna Therapeutics Company Profile 90

Figure mRNA Cancer Vaccines and Therapeutics Product Picture of Moderna Therapeutics 91

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Moderna Therapeutics 2017-2018 93

Table CureVac Company Profile 93

Figure mRNA Cancer Vaccines and Therapeutics Product Information of CureVac 94

Figure mRNA Cancer Vaccines and Therapeutics Product Information of CureVac 95

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of CureVac 2017-2018 95

Table Translate Bio Company Profile 96

Figure mRNA Cancer Vaccines and Therapeutics Product Picture of Translate Bio 97

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Translate Bio 2017-2018 97

Table BioNTech Company Profile 98

Figure mRNA Cancer Vaccines and Therapeutics Product Information of BioNTech 99

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of BioNTech 2017-2018 100

Table Sangamo Therapeutics Company Profile 100

Figure mRNA Cancer Vaccines and Therapeutics Product Picture of Sangamo Therapeutics 101

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Sangamo Therapeutics 2017-2018 101

Table Argos Therapeutics Company Profile 102

Figure mRNA Cancer Vaccines and Therapeutics Product Picture of Argos Therapeutics 103

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Argos Therapeutics 2017-2018 104

Table In-Cell-Art Company Profile 104

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of In-Cell-Art 2017-2018 106

Table eTheRNA Company Profile 107

Figure mRNA Cancer Vaccines and Therapeutics Product Information of eTheRNA 108

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of eTheRNA 2017-2018 108

Table Ethris Company Profile 109

Figure mRNA Cancer Vaccines and Therapeutics Product Information of Ethris 110

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Ethris 2017-2018 110

Table Tiba Biotechnology Company Profile 110

Figure mRNA Cancer Vaccines and Therapeutics Product Picture of Tiba Biotechnology 112

Table mRNA Cancer Vaccines and Therapeutics Expenses (M USD), R&D Share of Tiba Biotechnology 2017-2018 112

Figure Global mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 113

Table Global mRNA Cancer Vaccines and Therapeutics Revenue (M USD) Forecast by Regions (2020-2025) 114

Table Global mRNA Cancer Vaccines and Therapeutics Revenue (M USD) Forecast by Regions (2025-2030) 114

Figure Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Regions (2020-2030) 115

Figure Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Regions in 2025 115

Figure North America mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 116

Figure Europe mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 117

Figure Asia Pacific mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 118

Figure South America mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 119

Figure Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue (M USD) and Growth Rate Forecast (2020-2030) 120

Table Global mRNA Cancer Vaccines and Therapeutics Revenue (M USD) Forecast by Application (2020-2025) 120

Table Global mRNA Cancer Vaccines and Therapeutics Revenue (M USD) Forecast by Application (2025-2030) 121

Figure Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Application (2020-2030) 121

Table Research Programs/Design for This Report 123

Figure Bottom-up and Top-down Approaches for This Report 125

Figure Data Triangulation 126

Table Key Data Information from Secondary Sources 127

Table Key Data Information from Primary Sources 128



★調査レポート[世界のmRNA癌ワクチン及び治療薬市場規模・現状・予測2018-2030] (コード:QYR810ZA08)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のmRNA癌ワクチン及び治療薬市場規模・現状・予測2018-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆